Multimodal management has been proposed as key to any effective drug intervention in cachexia. This article attempts to reflect on clinical and regulatory considerations of multimodal management treatment as a regulatory requirement in anticachexia drug therapy. To date, no European Union (EU) regulatory guidelines have been published and therefore this review could attempt to present and discuss some central issues to consider when developing an anticachexia drug.
INTRODUCTION
There is an increased rise in scientific publications on cachexia (see Fig. 1 ; data sourced from http:// www.ncbi.nlm.nih.gov/pubmed) advocating multimodal management as key to any effective drug intervention. The rationale for this advocacy rests on the growing understanding of the multidimensional nature of fatigue and muscle wasting that has led to interest in care being provided in multidisciplinary hospital-based clinics for oncology/pall iative care settings [1, 2] . To date, no medicinal product in the EU has been approved for cachexia. A review of the investigational medicinal product clinical development programmes indicates that the phase III clinical trials carried out did not incorporate drug intervention into a multimodal treatment. Table 1 lists the investigational medicinal products and the respective clinical trials as well as the conditions used (information extracted from www.clinicaltrials.gov). The lack of unimodal treatment studies in cachexia to deliver effective treatment options coupled with the growing awareness that multiple components are responsible for the development of cachexia point towards the view that cachexia intervention should include multimodal treatment [3] . A cachexic multimodal management programme (MMP) would involve the use of background treatments tailored to the disease causing cachexia (i.e. cancer, heart failure, chronic obstructive pulmonary disease). To this end antiinflammatory agent/s, high protein intake, heart failure-specific treatments and an individually tailored resistance exercise regimen to counteract muscle wasting and fatigue amended by psychological support if needed and good symptom control (provided by early integrated supportive/palliative care) will be required. It is therefore understandable that developing a medicinal product for the whole cachexia indication (precachexic, cachexic and endstage cachexia) in combination with a MMP is extremely complex and associated with regulatory uncertainty as no EU guidelines have been developed on the subject. The issue is further complicated with the fact that different pathophysiologies lead to cachexia that, in principle, could affect the effectiveness of the MMP itself. For example, it is not unexpected that an MMP's resistance exercise regimen would be more effective in precachexic patient population than cachexic patients, as precachexic patients are more likely to respond to the exercise regimen (as muscle wasting would not be that advanced). However, not all cachexic patients could be considered the same; from a regulatory perspective, cancer patients, cardiac patients and HIV patients are considered different (because of the underlying pathophysiological state of the patient), and this concern of heterogeneity in cachexic patient populations has to be kept in mind by potential applicants as well as researchers as this complicates the regulatory decision-making process when regulators need to extrapolate the efficacy and safety results obtained from the pivotal clinical trials from one setting to another. The aim of this article is to examine the regulatory and clinical considerations for multimodal management as requirement for the clinical use of anticachexia drugs.
METHODS

Identification of multimodal management treatment options already approved by regulators in other indications
To identify relevant marketing authorizations of medicinal products for human use wherein the approved indication (i.e. label) contains the term diet, we performed a www.medicines.org.ie advanced search wherein all summary of product
KEY POINTS
MMPs including physical activity, nutrition, psychological support and palliative/supportive care may be effective to reduce variability in testing new drugs for cachexia.
The incorporation of multimodal management in clinical phase III trials requires careful considerations to reflect current best practice. 
RESULTS AND DISCUSSION
Regulatory and clinical considerations
The current framework in the EU is that to place a medicinal product in the EU market, a marketing authorization needs to be granted. For this, prospective applicants need to submit a dossier for regulatory evaluation. The EU marketing authorization (following the centralised procedure, see www.-EMA.europa.eu) can either be a full marketing authorization or one that is granted under conditions (conditional marketing authorisation [CMA] [4] ) or exceptional circumstances (exceptional marketing authorisation [eMA] [5]). A CMA or an eMA is granted following the evaluation of the data submitted wherein the Committee on Human Medicinal Products would conclude that there is insufficient efficacy or safety data for a full marketing authorization to be granted. To this effect, the applicant must prove that the product has a positive benefit/risk profile in the indication being claimed and that there is an inherent urgent unmet medical need for treatment; furthermore, the applicant's proposals on generating further data postlicensure must also be submitted for review (including their feasibility). These justifications would then be required to support the licensure of the medicinal product in order to outweigh the concern that the lack of a full marketing authorization is not available at that current time point. For the sake of clarity, the difference between a CMA and an eMA is that the postauthorization measures set in the CMA would eventually lead towards the switching to a 'full' marketing authorization, whereas with an eMA, a 'full comprehensive data' is not expected to be possible with the medicinal product postlicensure [6, 7] . It is therefore understandable that the current EU regulatory framework [6, 7] provides few options for prospective applicants of anticachexia drugs who face the challenge of developing treatments in heterogeneous patient populations in which extrapolation of efficacy and safety data need to be done (unless pivotal clinical trials in more than one setting, including confirmatory trials, are submitted). This makes clinical development programmes of such medicinal products resource intensive and complicated because unless an eMA (which is the exception and not the rule) can be issued, a full and comprehensive dataset is required. In order to explore on how to address this issue and foster a route to bring medicinal products faster to the market, the European Medicines Agency launched a 'pilot' project called 'adaptive licensing' whereby applicants first set their clinical development programmes on investigating selective and restricted indications (representative of the patient population studied in their phase II/III studies) and then widening the indication through postauthorization variations when the results of clinical trials would be available [8 & ]. Any clinical development should therefore be set with clear targeted selection criteria [for the randomized clinical trial (RCT)] that allow the identification and characterization of the population of interest that is an at-risk population with undisputable clinical need, where the criteria in setting the patient population should be based on instruments that are designed to measure comprehensively physical function (lower and upper limb, daily activities in real life), lean body mass, weight loss, disability (walking test) etc. Any cutoffs, should be clearly justified. Understandably, RCTs employing multimodal management as requirement for the clinical use of anticachexia drugs are expected to provide outcome data where bias in treatment effects are minimized whereby the drug effect on its own and drug along with multimodal management effect versus background therapy are clearly understood. Similarly, any clinical trials utilizing a 'basket trial' design (to optimize translation of the findings in a timely, but safe way for patients) matching patients with a rare mutation, regardless of tumour histology, to a drug that is expected to work through the mutated pathway also need to provide outcome data where uncertainties in treatment effects are minimized. For cancer cachexia, a well defined MMP including physical activity and resistance training, nutritional support providing adequate proteins, and defined and adequate cancer palliative and supportive care may reduce variability from background treatment to such an extend that variability from different tumour types becomes less important. In addition, the approach for development of clinical biomarkers (for cachexia) are expected to be clearly justified and validated, and that the population studied cover the whole spectrum and not just the precachexia population. Furthermore, the methodology for the diagnostic gold standard of cachexia should be fine-tuned, whereas specific biomarkers to be evaluated should be chosen to evaluate physiologic processes that are believed to be relevant to muscle wasting. It should be noted that biomarkers will be evaluated for their ability to discriminate between precachexia and cachexia states (status biomarkers/concurrent validity) and for their ability to predict important study outcomes (predictive validity). Furthermore, if a full set of dose-finding studies are not carried out, regulator's would be faced with problems in the decision-making phase if the pivotal clinical study in the end would only show borderline results or significant safety findings that may potentially have been avoidable with a lower, albeit still efficacious, dose.
Another important problem in the assessment of drugs for the treatment of cachexia is whether a combined improvement in lean muscle mass and in strength/performance is needed or whether a sole effect on a functional endpoint will suffice. Being cachexia a progressive chronic disorder, the stabilization or the improvement of functional parameters should suffice. Furthermore, in the past, drugs which have improved lean muscle mass have failed to show a significant improvement on functional endpoints. Therefore, a clinically meaningful effect on a well validated endpoint (i.e. walk test, hand grip strength, short physical performance battery, body-worn activity monitors) seems to be preferable. The approach to combine muscle mass measurements with patient-reported outcomes (cachexia-related symptoms) measured with well validated tools in placebo-controlled settings may also be considered.
Therefore, although from a clinical perspective, multimodal treatment incorporated in a drug intervention plan makes scientific sense, to date, no phase III clinical trials have been carried out incorporating cachexia-drug intervention into a multimodal treatment (see Table 1 ). It therefore intrigued us to explore if multimodal treatment has been incorporated in other classes of medicinal products. A search of approved licenses retrieved the SmPCs of 79 products. After filtering the hits to remove duplicates or products within the same global marketing authorization, 51 medicinal products remained. Analysing the indications of the authorized products, it is observed that the term 'diet' is included in the following clinical areas: drugs used in diabetes, alimentary tract and metabolism products, lipidmodifying agents, antigout preparations, drugs for treatment of hyperkalaemia and hyperphosphataemia, and other combinations of nutrients.
Interestingly, further analysis of the specific wording used in product labelling, we observe that the medicinal product is used as monotherapy but only after inadequately control of the condition by diet and exercise, for example metformin for use in type II diabetes, or else the medicinal product is to be used as an 'adjunct' to diet as, for example, in the case of atorvastatin and cholestagel. These labelling claims have value for multimodal management and anticachexia drugs, because they indicate that regulators do allow labelling claims of medicinal products to be an adjunct to nonpharmacological therapies; but, most importantly, for a medicinal product to promote an increase in lean body mass in an effective manner, the necessary building blocks to be able to do so must be present in situ.
CONCLUSION
Conversely, the incorporation of multimodal treatment in anticachexia drug therapy is expected to increase the effectiveness of intervention. This aspect is what appeals to pharmaceutical companies; however, at the same time, the incorporation of multimodal treatment in anticachexia drug therapy raises complex regulatory and clinical concerns that need to be kept in mind when designing RCTs so that outcomes are clear and robust enough for regulatory authorities to be able to conclude on the risk/benefit profile of the anticachexia drug therapy in combination with multimodal treatment and to arrive on adequate claims in the product label.
